[1]何娟,李安琪,李承新.抗CD20单克隆抗体在天疱疮治疗中的应用进展[J].中国皮肤性病学杂志,2021,(03):241-245.[doi:10.13735/j.cjdv.1001-7089.202004195]
 HE Juan,LI Anqi,LI Chengxin.Progress of Anti-CD20 Monoclonal Antibody in the Treatment of Pemphigus[J].The Chinese Journal of Dermatovenereology,2021,(03):241-245.[doi:10.13735/j.cjdv.1001-7089.202004195]
点击复制

抗CD20单克隆抗体在天疱疮治疗中的应用进展()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年03期
页码:
241-245
栏目:
专家论坛
出版日期:
2021-03-01

文章信息/Info

Title:
Progress of Anti-CD20 Monoclonal Antibody in the Treatment of Pemphigus
文章编号:
1001-7089(2021)03-0241-05
作者:
何娟12李安琪12李承新1
1.中国人民解放军总医院第一医学中心皮肤科,北京 100853; 2.南开大学医学院,天津 300071
Author(s):
HE Juan12LI Anqi12LI Chengxin1
(1.Department of Dermatology, the Frist Medical Center of PLA General Hospital, Beijing 100853, China; 2.Medical College of Nankai University, Tianjin 300071, China)
关键词:
天疱疮 抗CD20单克隆抗体 生物制剂 利妥昔单抗
Keywords:
Pemphigus Anti-CD20 monoclonal antibody Biological agent Rituximab
分类号:
R 758.66
DOI:
10.13735/j.cjdv.1001-7089.202004195
文献标志码:
A
摘要:
天疱疮的传统治疗药物为糖皮质激素和免疫抑制剂,但副作用较大且易复发。利妥昔单抗是第一代人鼠嵌合型抗CD20的单克隆抗体,与B淋巴细胞跨膜抗原CD20结合后可通过多种机制将其清除。目前利妥昔单抗常用于中重度天疱疮患者的治疗,不仅有助于改善病情、减少复发,而且可以减少糖皮质激素用量从而减少激素相关不良反应。新一代人源化的抗CD20单克隆抗体耐药发生率更低,B细胞清除能力更强,为天疱疮的治疗提供了新的选择。
Abstract:
Glucocorticoids and immunosuppressants are traditional treatment drugs for pemphigus but with large side effects and high recurrence rates.Rituximab is the first generation murine/human anti-CD20 monoclonal antibody, targeting CD20 antigen on the surface of B lymphocyte, leading to the elimination of B lymphocyte by many ways.Rituximab is used in the treatment of patients with moderate to severe pemphigus increasingly, not only improve the condition and reduce recurrence rates, but also reduce glucocorticoid dosage and related side effects.Next-generation humanized anti-CD20 antibody decreases the rate of resistance and enhances B cell clearance ability.It provides a new choice for the treatment of pemphigus.

参考文献/References:

[1] Schmidt E, Kasperkiewicz M, Joly P.Pemphigus [J].Lancet(London, England), 2019, 394(10201):882-894.
[2] Pollmann R, Schmidt T, Eming R, et al.Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches[J].Clin Rev Allergy Immunol, 2018, 54(1):1-25.
[3] Frampton JE.Rituximab: A review in pemphigus vulgaris[J].Am J Clin Dermatol, 2020, 21(1):149-156.
[4] Bilgic A, Murrell DF.What is novel in the clinical management of pemphigus[J].Expert Rev Clin Pharmacol, 2019, 12(10):973-980.
[5] 徐思嘉, 许人超, 潘萌, 等.寻常型天疱疮棘层松解的机制[J].中国皮肤性病学杂志, 2018, 32(4):451-455.
[6] Buonavoglia A, Leone P, Dammacco R, et al.Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy[J].Autoimmun Rev, 2019, 18(4):349-358.
[7] Saito M, Stahley SN, Caughman CY, et al.Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation[J].PLoS one, 2012, 7(12):e50696.
[8] Furue M, Kadono T.Pemphigus, a pathomechanism of acantholysis[J].Australas J Dermatol, 2017, 58(3):171-173.
[9] Amagai M, Stanley JR.Desmoglein as a target in skin disease and beyond[J].J Invest Dermatol,2012, 132(3 Pt 2):776-784.
[10] Didona D, Maglie R, Eming R, et al.Pemphigus: current and future therapeutic strategies[J].Front Immunol, 2019,10:1418.
[11] Leshem YA, David M, Hodak E, et al.A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab[J].Arch Dermatol Res, 2014, 306(1):67-74.
[12] Huang A, Madan RK, Levitt J.Future therapies for pemphigus vulgaris: Rituximab and beyond[J].Am Acad Dermatol, 2016,74(4):746-753.
[13] Amber KT, Hertl M.An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab[J].J Eur Acad Dermatol Venereol, 2015, 29(4):777-782.
[14] Russo I, Miotto S, Saponeri A, et al.Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study[J].Expert Opin Biol Ther,2020,20(6):637-678.
[15] Balighi K, Daneshpazhooh M, Mahmoudi H, et al.Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? [J].Arch Dermatol Res, 2019, 311(1):63-69.
[16] Wang HH, Liu CW, Li YC, et al.Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens[J].Acta Derm Venereol, 2015, 95(8):928-932.
[17] Harman KE, Brown D, Exton LS, et al.British association of dermatologists' guidelines for the management of pemphigus vulgaris 2017[J].Br J Dermatol, 2017, 177(5):1170-1201.
[18] Kaegi C, Wuest B, Schreiner J, et al.Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders[J].Front Immunol, 2019, 10:1990.
[19] 中国医疗保健国际交流促进会皮肤科分会.寻常型天疱疮诊断和治疗专家建议(2020)[J].中华皮肤科杂志, 2020, 53(1):1-7.
[20] Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus(Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial[J].Lancet(London, England), 2017, 389(10083):2031-2040.
[21] Chen DM, Odueyungbo A, Csinady E, et al.Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect[J].Br J Dermatol,2020,182(5):1111-1119.
[22] Keeley JM, Bevans SL, Jaleel T, et al.Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients[J].J Dermatolog Treat, 2019, 30(4):340-345.
[23] Ahmed AR, Nguyen T, Kaveri S, et al.First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up[J].Int Immunopharmacol, 2016, 34:25-31.
[24] Kolesnik M, Becker E, Reinhold D, et al.Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication[J].J Eur Acad Dermatol Venereol, 2014, 28(6):771-780.
[25] Rapp M, Pentland A, Richardson C.Successful treatment of pemphigus vulgaris with of atumumab[J].J Drugs Dermatol, 2018, 17(12):1338-1339.
[26] Ellebrecht CT, Choi EJ, Allman DM, et al.Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris[J].JAMA Dermatol, 2014, 150(12):1331-1335.
[27] Tavakolpour S, Mahmoudi H, Balighi K,et al.Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review[J].Int Immunopharmacol, 2018, 54:131-138.
[28] Wei KC, Wang YH, Wang WH, et al.Fatal infection of pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab[J].J Eur Acad Dermatol Venereol, 2017, 31(8):e350-e351.
[29] Yoo DS, Kim JH, Kim SC.Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab[J].JAAD Case Rep, 2020, 6(2):83-85.

相似文献/References:

[1]黄芳,靳耀锋,冯义国,等.抗桥粒芯蛋白抗体对天疱疮的临床诊断价值[J].中国皮肤性病学杂志,2015,(03):318.[doi:10.13735/j.cjdv.1001-7089.201407027]
 HUANG Fang,JIN Yao feng,FENG Yi guo,et al.The Clinical Diagnostic Value of Antidesmoglein Antibody in Pemphigus[J].The Chinese Journal of Dermatovenereology,2015,(03):318.[doi:10.13735/j.cjdv.1001-7089.201407027]
[2]来学民,赵玉铭.天疱疮患者毛囊中自身抗体与病情相关性的研究进展[J].中国皮肤性病学杂志,2015,(06):632.[doi:10.13735/j.cjdv.1001-7089.201406172]
 LAI Xue min,ZHAO Yu ming.Advances in the Association of Antibodies in the Follicles of Plucked Hair with Disease Severity in Pemphigus[J].The Chinese Journal of Dermatovenereology,2015,(03):632.[doi:10.13735/j.cjdv.1001-7089.201406172]
[3]黄芳,魏雅风,靳耀峰,等.热休克蛋白70在天疱疮中的意义[J].中国皮肤性病学杂志,2015,(08):790.[doi:10.13735/j.cjdv.1001-7089.201410061]
 HUANG Fang,WEI Ya feng,JIN Yao feng,et al.The Clinical Significance of Heat Shock Protein 70 in Pemphigus[J].The Chinese Journal of Dermatovenereology,2015,(03):790.[doi:10.13735/j.cjdv.1001-7089.201410061]
[4]元慧杰,刘芝翠,潘萌,等.天疱疮患者外周血滤泡辅助性T细胞的表达及其与血清抗Dsg抗体滴度的相关性[J].中国皮肤性病学杂志,2015,(09):894.[doi:10.13735/j.cjdv.1001-7089.201501015]
 YUAN Hui jie,LIU Zhi cui,PAN Meng,et al.The Expression of Follicular Helper T Cells in Peripheral Blood of Pemphigus Patients and the Correlation between it and Anti Dsg1/Dsg3 Autoantibody Titer[J].The Chinese Journal of Dermatovenereology,2015,(03):894.[doi:10.13735/j.cjdv.1001-7089.201501015]
[5]来学民,赵玉铭,王雅坤.天疱疮患者头发毛囊直接免疫荧光检测及其临床意义探讨[J].中国皮肤性病学杂志,2015,(11):1134.[doi:10.13735/j.cjdv.1001-7089.201503060]
 LAI Xue min,ZHAO Yu ming,WANG Ya kun.The Detection and Clinical Significance of Direct Immunofluorescence of Antibodies in the Follicles of Patients with Pemphigus[J].The Chinese Journal of Dermatovenereology,2015,(03):1134.[doi:10.13735/j.cjdv.1001-7089.201503060]
[6]王慧丛*,付萍.Th1,Th2,Th17及Treg与寻常型天疱疮的相关性[J].中国皮肤性病学杂志,2016,(06):582.[doi:10.13735/j.cjdv.1001-7089.201511011]
 WANG Hui-cong*,FU Ping.The Correlation Study of Th1, Th2, Th17 and Treg Cells in Pemphigus Vulgaris[J].The Chinese Journal of Dermatovenereology,2016,(03):582.[doi:10.13735/j.cjdv.1001-7089.201511011]
[7]王炜.糖皮质激素对天疱疮和类天疱疮患者诱发糖尿病的临床研究[J].中国皮肤性病学杂志,2016,(07):705.[doi:10.13735/j.cjdv.1001-7089.201410036]
 WANG Wei.Clinical Study of Glucocorticoid on Pemphigus and Pemphigoid Patients Induced by Diabetes[J].The Chinese Journal of Dermatovenereology,2016,(03):705.[doi:10.13735/j.cjdv.1001-7089.201410036]
[8]杨刚,张琪,谭城.5-氨基酮戊酸光动力疗法治疗慢性家族性良性天疱疮1例及文献复习[J].中国皮肤性病学杂志,2016,(11):1138.[doi:10.13735/j.cjdv.1001-7089.201606026]
 YANG Gang,ZHANG Qi,TAN Cheng.Photodynamic Therapy of Familial Benign Chronic Pemphigus using 5-Aminolevulinic Acid:A Case Report and Literature Review[J].The Chinese Journal of Dermatovenereology,2016,(03):1138.[doi:10.13735/j.cjdv.1001-7089.201606026]
[9]李志量,荆可,李锁,等.寻常型天疱疮患者血清IgG与HaCaT细胞共培养构建天疱疮细胞模型[J].中国皮肤性病学杂志,2018,(01):8.[doi:10.13735/j.cjdv.1001-7089.201707059]
 LI Zhiliang,JING Ke,LI Suo,et al.Establishment of Cell Model of Pemphigus Using Co-cultured HaCaT Cells with Pemphigus Vulgaris(PV)-IgG[J].The Chinese Journal of Dermatovenereology,2018,(03):8.[doi:10.13735/j.cjdv.1001-7089.201707059]
[10]蒋存火,何丽莎.儿童寻常型天疱疮1例[J].中国皮肤性病学杂志,2013,(06):605.
 JIANG Cunhuo,HE Lisha.A Case of Childrens Pemphigus Vulgaris[J].The Chinese Journal of Dermatovenereology,2013,(03):605.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81972936); 首都临床特色应用研究(Z181100001718038); 解放军总医院科技创新苗圃基金项目(18KMM10)
[通信作者] 李承新,E-mail:chengxinderm@163.com
更新日期/Last Update: 2021-02-10